StockData
SPTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Seaport Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$17.79−0.04 (-0.22%)

Close on Oct 19, 2026

Market cap
$626.85M
P/E (TTM)
–
Dividend yield
–

Seaport Therapeutics statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison

Valuation

MeasureSeaport TherapeuticsIndustry median
Market Cap$952.31M$166.30M
Enterprise Value$679.00M$88.19M
PB Ratio2.252.03
P/TBV Ratio2.252.29

Balance sheet

MeasureSeaport TherapeuticsIndustry median
Cash & Short-Term Investments$273.31M$61.43M
Net Cash (Debt)$273.31M$15.35M
Net Cash Per Share$5.11$0.66
Equity (Book Value)$422.60M$49.09M
Book Value Per Share$7.89$1.37
Tangible Book Value$422.60M$23.52M
Working Capital$266.50M$76.81M

Financial position

MeasureSeaport TherapeuticsIndustry median
Current Ratio18.003.34
Quick Ratio17.442.44

Shares

MeasureSeaport TherapeuticsIndustry median
Shares Outstanding53,530,60058,127,000
Shares Change (QoQ)1962.6%0.54%
Float19,804,50049,136,700
Shares Held by Insiders63.0%11.6%
Shares Held by Institutions69.9%59.4%

Scores

MeasureSeaport TherapeuticsIndustry median
Altman Z-Score30.03-0.22

Calculated by StockData from Seaport Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.